FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240930790> ?p ?o ?g. }

• W4240930790 endingPage "708" @default.
• W4240930790 startingPage "708.1" @default.
• W4240930790 abstract "<h3>Background</h3> Tumor Necrosis Factor alpha (TNF) plays a major role in the pathogenesis of multiple sclerosis (MS). However, attempts to use TNF Inhibitor (TNF-I) for the treatment of MS have been unsuccessful and even led to increased MS-attack frequency. Several case-reports and small patient-series have implicated TNF-I treatment with occurrence of both central and peripheral demyelinating conditions¹. All patients in Denmark with inflammatory arthritis requiring treatment with TNF-I are registered in the national database DANBIO with continuous recordings of clinical, serological and radiographic data. Likewise, all patients with an established diagnosis of MS are included in the Danish Multiple Sclerosis Registry (DMSR) with a coverage exceeding 95% of all eligible cases. <h3>Objectives</h3> To investigate whether TNF-I treatment in arthritis patients is associated with an increased risk of MS based on prospectively registered observational data from the DANBIO registry and DMSR. <h3>Methods</h3> By linking data from DANBIO and DMSR we identified all individuals with new onset MS in a cohort of 30 490 patients (62.5% rheumatoid arthritis, 8.9% ankylosing spondylitis, 14.1% psoriatric arthritis, 14.6% other arthritides). Among these, 10 296 started TNF-I therapy during follow-up from January 2000 to the end of 2012. Patients registered with MS before entry were excluded from the analyses. Standardized Incidence Ratios (SIR) of MS among ever TNF-I users and TNF-I naïve were estimated using standardized incidence rates of MS from the general populations and person-years at risk. <h3>Results</h3> During 113 506 person-years of follow-up there were 7 incident cases of MS, yielding an overall SIR of 1.27 (95% CI 0.51-2.62). There was no difference between SIR of MS observed in patients ever starting TNF-I therapy (SIR=1.30, 95% CI 0.35-3.32) or TNF-I naïve patients (SIR=1.24, 95% CI 0.26-3.63). <h3>Conclusions</h3> We were unable to demonstrate an increased risk of MS in arthritis patients treated with TNF-I. However, this does not necessarily exclude that inhibition of TNF could lead to demyelinating conditions in susceptible patients. Based on several published cases of demyelinating adverse events occurring after TNF-I treatment the disease manifestations may deviate from the common pattern of recurrent episodes found in classical MS and thus escape inclusion into DMSR. <h3>References</h3> Theibich A, Dreyer L, Magyari M, Locht H. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol. 2014 May;33(5):719-23. doi: 10.1007/s10067-013-2419-8. Epub 2013 Nov 8. <h3>Acknowledgements</h3> Thanks to all the departments of rheumatology in Denmark for reporting to the DANBIO registry. <h3>Disclosure of Interest</h3> None declared" @default.
• W4240930790 created "2022-05-12" @default.
• W4240930790 creator A5004151210 @default.
• W4240930790 creator A5007690958 @default.
• W4240930790 creator A5052693500 @default.
• W4240930790 creator A5053531204 @default.
• W4240930790 creator A5080616680 @default.
• W4240930790 creator A5085365494 @default.
• W4240930790 date "2015-06-01" @default.
• W4240930790 modified "2023-09-23" @default.
• W4240930790 title "SAT0155 Multiple Sclerosis During Tumor Necrosis Factor Inhibitor Treatment for Arthritis – A Population Based Study from Danbio and the Danish Multiple Sclerosis Registry" @default.
• W4240930790 doi "https://doi.org/10.1136/annrheumdis-2015-eular.2124" @default.
• W4240930790 hasPublicationYear "2015" @default.
• W4240930790 type Work @default.
• W4240930790 citedByCount "0" @default.
• W4240930790 crossrefType "journal-article" @default.
• W4240930790 hasAuthorship W4240930790A5004151210 @default.
• W4240930790 hasAuthorship W4240930790A5007690958 @default.
• W4240930790 hasAuthorship W4240930790A5052693500 @default.
• W4240930790 hasAuthorship W4240930790A5053531204 @default.
• W4240930790 hasAuthorship W4240930790A5080616680 @default.
• W4240930790 hasAuthorship W4240930790A5085365494 @default.
• W4240930790 hasConcept C120665830 @default.
• W4240930790 hasConcept C121332964 @default.
• W4240930790 hasConcept C126322002 @default.
• W4240930790 hasConcept C138885662 @default.
• W4240930790 hasConcept C164622146 @default.
• W4240930790 hasConcept C17991360 @default.
• W4240930790 hasConcept C203014093 @default.
• W4240930790 hasConcept C2776260265 @default.
• W4240930790 hasConcept C2777077863 @default.
• W4240930790 hasConcept C2777226972 @default.
• W4240930790 hasConcept C2777402515 @default.
• W4240930790 hasConcept C2777575956 @default.
• W4240930790 hasConcept C2779722408 @default.
• W4240930790 hasConcept C2780640218 @default.
• W4240930790 hasConcept C2908647359 @default.
• W4240930790 hasConcept C41895202 @default.
• W4240930790 hasConcept C61511704 @default.
• W4240930790 hasConcept C71924100 @default.
• W4240930790 hasConcept C72563966 @default.
• W4240930790 hasConcept C99454951 @default.
• W4240930790 hasConceptScore W4240930790C120665830 @default.
• W4240930790 hasConceptScore W4240930790C121332964 @default.
• W4240930790 hasConceptScore W4240930790C126322002 @default.
• W4240930790 hasConceptScore W4240930790C138885662 @default.
• W4240930790 hasConceptScore W4240930790C164622146 @default.
• W4240930790 hasConceptScore W4240930790C17991360 @default.
• W4240930790 hasConceptScore W4240930790C203014093 @default.
• W4240930790 hasConceptScore W4240930790C2776260265 @default.
• W4240930790 hasConceptScore W4240930790C2777077863 @default.
• W4240930790 hasConceptScore W4240930790C2777226972 @default.
• W4240930790 hasConceptScore W4240930790C2777402515 @default.
• W4240930790 hasConceptScore W4240930790C2777575956 @default.
• W4240930790 hasConceptScore W4240930790C2779722408 @default.
• W4240930790 hasConceptScore W4240930790C2780640218 @default.
• W4240930790 hasConceptScore W4240930790C2908647359 @default.
• W4240930790 hasConceptScore W4240930790C41895202 @default.
• W4240930790 hasConceptScore W4240930790C61511704 @default.
• W4240930790 hasConceptScore W4240930790C71924100 @default.
• W4240930790 hasConceptScore W4240930790C72563966 @default.
• W4240930790 hasConceptScore W4240930790C99454951 @default.
• W4240930790 hasIssue "Suppl 2" @default.
• W4240930790 hasLocation W42409307901 @default.
• W4240930790 hasOpenAccess W4240930790 @default.
• W4240930790 hasPrimaryLocation W42409307901 @default.
• W4240930790 hasRelatedWork W1505374175 @default.
• W4240930790 hasRelatedWork W1974193246 @default.
• W4240930790 hasRelatedWork W1977385433 @default.
• W4240930790 hasRelatedWork W1997363697 @default.
• W4240930790 hasRelatedWork W2035524760 @default.
• W4240930790 hasRelatedWork W2087248190 @default.
• W4240930790 hasRelatedWork W2111965497 @default.
• W4240930790 hasRelatedWork W2171255147 @default.
• W4240930790 hasRelatedWork W2743764001 @default.
• W4240930790 hasRelatedWork W2955471408 @default.
• W4240930790 hasVolume "74" @default.
• W4240930790 isParatext "false" @default.
• W4240930790 isRetracted "false" @default.
• W4240930790 workType "article" @default.